What is the recommended dosing schedule for venlafaxine (including extended‑release and immediate‑release formulations)?

Venlafaxine Dosing

For immediate-release venlafaxine, start at 75 mg/day divided into 2-3 doses with food, increase by up to 75 mg every 4 days as tolerated to a target of 150-225 mg/day, with a maximum of 375 mg/day for severely depressed patients; for extended-release formulations, start at 75 mg once daily and follow the same titration schedule. 1

Immediate-Release (IR) Formulation

Starting Dose

• Begin at 75 mg/day divided into 2 or 3 doses, taken with food 1
• Older adults should start at approximately 37.5 mg/day (50% of standard adult dose) due to increased risk of adverse reactions 2, 3

Titration Schedule

• Increase by up to 75 mg/day at intervals of no less than 4 days 1
• Target therapeutic range is 150-225 mg/day for most patients 2, 1
• Maximum dose is 375 mg/day in three divided doses for severely depressed patients, particularly inpatients 1

Dose-Response Relationship

• 75 mg/day is the minimum effective dose but predominantly affects serotonin reuptake only 4
• 150-225 mg/day provides dual serotonin-norepinephrine action and shows significantly better efficacy than lower doses 5, 4
• Doses >225 mg/day showed no additional benefit in moderately depressed outpatients, but severely depressed inpatients responded to mean doses of 350 mg/day 1

Extended-Release (ER/XR) Formulation

Starting Dose

• Begin at 75 mg once daily in the morning 5, 3, 6
• Alternative lower starting dose of 37.5 mg once or twice daily may be used for patients sensitive to side effects 5, 6

Titration Schedule

• Increase by 75 mg weekly as tolerated 5, 6
• Target therapeutic range is 150-225 mg/day 5, 3, 6
• Maximum dose is 225 mg/day for routine outpatient depression 5
• Some severely depressed patients may require up to 300 mg/day 3

Advantages Over Immediate-Release

• Once-daily dosing improves convenience and adherence 5, 3
• 63% reduction in nausea intensity compared to immediate-release formulation 7
• Produces less intensive peak effects while maintaining equivalent bioavailability (40-45%) 7

Special Population Dosing Adjustments

Renal Impairment

• Mild to moderate renal impairment (GFR 10-70 mL/min): Reduce total daily dose by 25% 1
• Hemodialysis patients: Reduce total daily dose by 50% 1
• Individual variability in clearance may require further dose reduction 1

Hepatic Impairment

• Mild to moderate hepatic impairment: Reduce total daily dose by 50% 1
• Individual variability may necessitate reductions exceeding 50% 1

Elderly Patients

• No age-based dose adjustment required, but start at approximately 50% of standard adult dose (37.5 mg/day) 2, 3, 1
• Exercise extra care when increasing doses 1

Critical Monitoring Requirements

Blood Pressure Monitoring

• Mandatory at doses >150 mg/day due to dose-dependent hypertension risk 5, 3, 6
• Among normotensive older adults, 9.8% developed elevated BP at doses ≥225 mg/day versus 1.9% at lower doses 8
• Blood pressure typically normalizes as dose is reduced during tapering 5

Orthostatic Hypotension

• 22.4% of older adults at doses ≥225 mg/day developed new-onset orthostatic hypotension versus 16.8% at lower doses 8
• Patients with orthostatic hypotension are significantly more likely to fall 8
• Check sitting and standing blood pressure at baseline and during treatment 3

Early Assessment

• Assess patient status, therapeutic response, and adverse effects within 1-2 weeks of initiation 2
• Allow 4-6 weeks at therapeutic dose (150-225 mg/day) before declaring treatment failure 3, 6
• Modify treatment if inadequate response after 6-8 weeks 2

Additional Monitoring

• Watch for behavioral activation, agitation, hypomania, or suicidal thinking, especially in patients ≤24 years old 3
• Monitor for serotonin syndrome if patient takes other serotonergic medications 3

Therapeutic Drug Monitoring

Target Concentration Range

• Active moiety (venlafaxine + O-desmethylvenlafaxine): 140-600 ng/mL 9
• O-desmethylvenlafaxine alone: 85-302 ng/mL 9
• Higher concentrations within this range increase probability of response in nonresponders due to dual mechanism of action 9
• Supratherapeutic concentrations increase risk of adverse reactions 9

When to Use TDM

• Suspected noncompliance 3
• Drug interactions 3
• Switching between generic and brand formulations 3
• Pharmacogenetic variations (CYP2D6 polymorphisms) 3, 4
• Nonresponse at lower concentrations 9

Discontinuation Protocol

Tapering Requirements

• Never stop abruptly—venlafaxine carries markedly higher discontinuation syndrome risk than other antidepressants due to short elimination half-life (5 hours for venlafaxine, 12 hours for metabolite) 5, 3, 4
• Minimum taper: 10-14 days for standard discontinuation 3, 1
• Slower taper: 10% reductions per week or per month (approximately 22.5 mg weekly decrements) may be necessary and significantly reduces withdrawal distress 5
• Some patients require tapering over several months 5

Withdrawal Symptoms

• Common symptoms include dizziness, nausea, headache, irritability, anxiety, increased pain perception, dysphoria, insomnia, and anhedonia 5, 3
• Protracted withdrawal syndrome may develop months after complete discontinuation 5
• If intolerable symptoms occur, resume previous dose and taper more gradually 1

Maintenance Treatment Duration

• Continue for 4-9 months after satisfactory response in first episode of major depression 2
• Longer duration (potentially indefinite) for patients with ≥2 episodes 2
• Recurrence probability: 50% after first episode, 70% after two episodes, 90% after three episodes 2, 3

Common Adverse Effects

Dose-Dependent Effects

• Nausea is most common, highest during first 2 weeks, dose-dependent, and most common reason for discontinuation 5, 10
• Hypertension occurs primarily at doses ≥225 mg/day 1, 4
• Diaphoresis, tremors, tachycardia, anxiety increase at higher doses due to norepinephrine reuptake inhibition 4

General Adverse Effects

• Dry mouth, decreased appetite, constipation, dizziness, somnolence, insomnia, sweating, sexual dysfunction 5, 3
• Dysuria occurs in up to 7% of patients and is dose-dependent 4

Drug Interactions

Absolute Contraindications

• Do not combine with MAOIs—risk of severe serotonin syndrome 3, 1
• Allow 14 days between stopping MAOI and starting venlafaxine 1
• Allow 7 days after stopping venlafaxine before starting MAOI 1

Linezolid and Methylene Blue

• Do not start venlafaxine in patients receiving linezolid or IV methylene blue 1
• If urgent treatment with linezolid/methylene blue needed in patient on venlafaxine: stop venlafaxine promptly, administer linezolid/methylene blue, monitor for serotonin syndrome for 7 days or 24 hours after last dose (whichever comes first) 1
• Resume venlafaxine 24 hours after last dose of linezolid/methylene blue 1

Other Serotonergic Agents

• Exercise caution with SSRIs, triptans, tramadol, St. John's Wort—may compound serotonin syndrome risk 3

Pharmacokinetic Considerations

• Venlafaxine is metabolized to active metabolite O-desmethylvenlafaxine by CYP2D6 4
• Venlafaxine and desvenlafaxine have low protein binding and do not inhibit CYP enzymes, making them favorable options when drug-drug interactions are a concern 4
• Venlafaxine may be subject to interactions with CYP2D6 inhibitors 4